Immune Design CS shares had a trading volume of 279K in the last trading session. Overall, volume was down 84.15% under the stocks normal daily volume.
Traders are a little more bullish on the company lately if you take into consideration the downtick in short interest. The company recorded a fall in short interest from September 29, 2017 to October 13, 2017 of -0.52%. Short shares decreased 10,881 over that timeframe. With short interest at 2,097,288 and short average daily volume at 128,139, the short-interest ratio is 16.0 and the short interest percentage is 0.04% as of October 13.
There has been some buying insider activity on Immune Design CS (NASDAQ:IMDZ) recently. Director Franklin M. Berger purchased 25,000 shares at an average price of $4.58 on October 30th. That brings the Director’s holdings to $343,500 as reported to the SEC. Peter Svennilson, Director reported the purchase of 2,681,000 shares. The shares were purchased at an average price of $4.10. Svennilson now owns $10,992,100 of the stock per the Form 4 SEC filing.
Director Lewis W. Coleman acquired 65,000 shares at an average price of $4.07 on Fri the 27th. The Director now owns $508,750 of the stock per an SEC filing yesterday.
These funds have shifted positions in (IMDZ). As of quarter end Citigroup Inc had sold 83 shares trimming its holdings by 72.8%. The value of the investment in (IMDZ) decreased from $1,000 to $0 a change of $1,000 for the reporting period. Trexquant Investment Lp trimmed its investment by selling 16,892 shares a decrease of 54.2% as of 09/30/2017. Trexquant Investment Lp now holds 14,260 shares with a value of $148,000. The value of the position overall is down by 51.3%.
As of the end of the quarter California State Teachers Retirement System had disposed of a total of 2,455 shares trimming its position 8.1%. The value of the total investment in Immune Design CS went from $294,000 to $287,000 a change of 2.4% since the last quarter. As of quarter end Brookside Capital Management LLC had acquired a total of 909,613 shares growing its stake by 233.6%. The value of the investment in IMDZ went from $3,797,000 to $13,445,000 increasing 254.1% quarter over quarter.
Equity analyst Royal Bank Of Canada released guidance on IMDZ with a rating of “Outperform”.
In the market the company is trading unchanged from yesterday’s close of 4.32. Immune Design CS currently has a P/E ratio of N/A and the market cap of the company is 207.85M. As of the last earnings report the EPS was $-2.13 with 48.06M shares now outstanding.
Immune Design Corp., launched on February 20, 2008, is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is involved in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials..